After a trickle of rough news cycles for the storied marque, a glimpse of Jaguar’s future has emerged. A trademark ...

Michael Guy, D.V.M., M.S., Ph.D., Jaguar's Vice President of Preclinical and Nonclinical Studies. "Canalevia-CA1 is an important prescription drug for the veterinary community and the thousands of ...

"Diarrhea is a highly neglected and unmet medical need in dogs and people undergoing cancer treatment," said Lisa Conte, Jaguar's president and CEO. "Jaguar is deeply committed to supporting the ...

Canalevia ®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA By prescription only, Canalevia-CA1 is a canine-specific ...

The product is the only FDA conditionally approved oral plant-based prescription treatment for CID in dogs, derived from the Croton lechleri tree. Jaguar Health emphasizes its commitment to ...

"Diarrhea is a highly neglected and unmet medical need in dogs and people undergoing cancer treatment," said Lisa Conte, Jaguar's president and CEO. "Jaguar is deeply committed to supporting the ...

SAN FRANCISCO - Jaguar Health, Inc. (NASDAQ:JAGX) has received a renewal from the U.S. Food and Drug Administration (FDA) for the conditional approval of its canine-specific drug, Canalevia-CA1, to ...